Zymeworks Inc.
No SEC Form 4 filings for $ZYME in the last 30 days.
Zymeworks Inc. (ZYME) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex991q22026_earningsxrelea.htm EX-99.1 Document Zymeworks Provides Corporate Update and Reports Second Quarter 2026 Financial Results • August 25, 2026 U.S. PDUFA target action date for zanidatamab has potential to unlock a $250 million U.S. approval milestone and up to
The article says Canada’s biotech sector has seen a strong 12-month run, with listed companies raising $2.4 billion on public markets and excluding Apotex’s $1.5 billion June IPO. It highlights several Canadian biotechs, especially AbCellera Biologics, which plans to report key human efficacy results this quarter for a menopause hot-flash treatment. It also notes foreign investors dominate funding.
Zymeworks Inc. agreed to acquire Theravance Biopharma, adding YUPELRI (revefenacin) for COPD. The deal values Theravance at $17/share, with a $350 million non-recourse note and $219 million cash plus Theravance’s estimated $360 million net cash at closing. YUPELRI U.S. net sales were $266.6M in 2025. Expected close in H2 2026.
Over the past 7 days, alphai's AI scored 2 news stories mentioning ZYME (Zymeworks Inc.). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
Recent ZYME coverage spans mergers & acquisitions, financial news and earnings.
Near-term catalysts cluster in 2H 2026: FDA action dates for zanidatamab, plus deal closing and milestone-driven cash flow expectations.
Sector-level framing only, with no new Zymeworks-specific facts.
Deal terms and YUPELRI cash-flow profile should support a positive re-rating, but near-term royalty impact and integration costs add uncertainty.
Analyst target increases and maintained Buy/Overweight can support near-term sentiment, but the article provides no new clinical or financial datapoint.
The key tradable change is the earnings event timing plus the absence of a call, tied to deal-closing expectations.
alphai scores every news story that mentions ZYME with an AI model for sentiment and relevance, and aggregates insider trades from Zymeworks Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Zymeworks Inc. (ZYME) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex991q22026_earningsxrelea.htm EX-99.1 Document Zymeworks Provides Corporate Update and Reports Second Quarter 2026 Financial Results • August 25, 2026 U.S. PDUFA target action date for zanidatamab has potential to unlock a $250 million U.S. approval milestone and up to
7 min readThe article says Canada’s biotech sector has seen a strong 12-month run, with listed companies raising $2.4 billion on public markets and excluding Apotex’s $1.5 billion June IPO. It highlights several Canadian biotechs, especially AbCellera Biologics, which plans to report key human efficacy results this quarter for a menopause hot-flash treatment. It also notes foreign investors dominate funding.
7 min readZymeworks Inc. agreed to acquire Theravance Biopharma, adding YUPELRI (revefenacin) for COPD. The deal values Theravance at $17/share, with a $350 million non-recourse note and $219 million cash plus Theravance’s estimated $360 million net cash at closing. YUPELRI U.S. net sales were $266.6M in 2025. Expected close in H2 2026.
5 min readTruist kept a Buy rating on Zymeworks (NASDAQ:ZYME) and raised its price target to $31 from $28 on July 7, citing updated models and expectations for a rebound after a softer start, including strength in fiscal Q2 for covered commercial franchises. Wells Fargo also raised its target to $37 from $34 and maintained Overweight, pointing to the Theravance Biopharma acquisition as supportive for future royalty portfolio buildout.
4 min readZymeworks Inc. (Nasdaq: ZYME) said it will release second-quarter 2026 financial results after market close on Aug. 6, 2026. It will not hold a post-results earnings call due to its previously announced proposed acquisition of Theravance Biopharma. The company expects to update investors after the acquisition closes.
2 min readZymeworks Inc. (Nasdaq:ZYME) said it will pay $929M in cash to acquire Theravance Biopharma Inc. (Nasdaq:TBPH). The offer is $17 per Theravance share, 3.6% below the prior close. Theravance’s ampreloxetine failed a March trial; its only marketed drug is Yupelri. Deal includes a one-year ampreloxetine monetization split and about $2.5B in Irish tax attributes.
4 min readZymeworks Inc. (ZYME) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-2.1 2 d156494dex21.htm EX-2.1 EX-2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER By and Among THERAVANCE BIOPHARMA, INC. ZYMEWORKS INC. and ZYMEWORKS MERGER SUB 1 Dated as of June 28, 2026 TABLE OF CONTENTS Page ARTICLE I THE MERGER Section 1.1 The Merger 2 Section 1.2 Closing 2
4 min readZymeworks said it will acquire Theravance Biopharma in a $929 million cash deal, according to the company. The transaction is expected to affect Zymeworks’ shareholders and is being watched by investors for its impact on future pipeline and financial outlook. TBPH shares were reported down in pre-market trading.
2 min readZymeworks Inc. ( NASDAQ:ZYME ) stock is surging on Monday, with a session volume of 2.17 million, compared to an average volume of 728.75K, according to Benzinga Pro.
3 min readZymeworks (ZYME) delivered earnings and revenue surprises of +13.33% and -2.31%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
3 min read
